Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Immunotherapies for the treatment of high-risk MM

Michael O’Dwyer • 18 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies CAR-T Daratumumab NK-Cell Therapy

Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, talks on the treatment and prognosis of high-risk multiple myeloma (MM) patients and the importance of immunotherapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael O’Dwyer

3:31
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study
Michael O’Dwyer • 30 Nov 2020
5:14
Current myeloma cellular therapy landscape and horizon scan
Michael O’Dwyer • 30 Nov 2020
2:01
Cellular therapy: NK-cells as a model
Michael O’Dwyer • 21 May 2020
5:14
NK-cell enhancement: TRAIL variant
Michael O’Dwyer • 18 May 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals